Bayer Schering Pharma AG

From Wikipedia, the free encyclopedia

Bayer Schering PharmaAG
Type	Subsidiary
Founded	1851 Schering 2006 merged
Headquarters	Berlin-Wedding, Germany
Key people	Hubertus Erlen, CEO
Industry	Pharmaceutical
Products	Gynaecology & Andrology Special therapeutics Diagnostical devices & Nuclear medicine Oncology
Revenue	€ 10.267 billion (2007)
Owner	Bayer
Employees	26,000 (2004)
Website	www.bayerscheringpharma.de

Bayer Schering Pharma AG is a research-centered pharmaceutical company that was formed by the merger of Schering with Bayer on December 29, 2006. The company was originally founded in 1851 by Ernst Schering (1824-1889). The company employs more than 26,000 people in 140 subsidiaries all over the world. The company's headquarters are in Berlin-Wedding, Germany and the forerunner company Schering's annual gross revenue was nearly € 5 billion (2003). They retain the largest German manufacturing facility which is located in Bergkamen. The company focuses on the business areas of gynaecology & andrology, oncology and also special therapeutics, diagnostical devices & nuclear medicine. Schering best-known product is their line of combined oral contraceptive pills.

[edit] Bayer's Takeover Bid

On March 13, 2006, Merck KGaA announced a €14.6bn bid for Schering [1]. The offer document was due to be issued in early April 2006.

Merck's takeover bid was surpassed by Bayer's $19.5B white-knight bid for Schering on March 23, 2006. In June 2006 Bayer finally bought the majority of shares, over 96%. A domination agreement using the code name "Step One" was used for the take-over. On February 17, 2007 the company publicly announced that 1,000 jobs would be cut through voluntary redundancy from the Berlin operations with effect until March 2008.